Navigation Links
BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Date:1/19/2011

release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations related to regulatory actions on BMN 701 and the development and efficacy of BMN 701. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities, results and timing of current and planned preclinical studies and clinical trials related to such product; our ability to successfully manufacture the product; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2009 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  VigeneTech, Inc, in collaboration with ... Data Analysis Software, an OEM software solution for ... develops and offers varieties of bead-based multi-analyte immunoassay ... support of VigeneTech,s data analysis software, FCS data ... easily reported LEGENDplex™ software is ...
(Date:7/28/2014)... Research and Markets  has announced the addition of the ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... pain in the human body,s joints such as wrists, fingers, ... the tissues that surround the joints and in other organs. ... usually just mild pain around the joints coupled with stiffness ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
Breaking Medicine Technology:VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4
... Thomson CompuMark , the global leader in trademark ... Reuters, today announced the launch of Global Pharmaceutical ... intelligence in a single online report. Avoiding ... to prescription errors, is a critically important public health ...
... Span-America Medical Systems, Inc. (NASDAQ:  SPAN) will provide ... call on Friday, February 3, 2012, covering results for ... after the regular close of trading the preceding day. ... will be available online at www.spanamerica.com under ...
Cached Medicine Technology:Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 2Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 3
(Date:7/28/2014)... New York, NY (PRWEB) July 28, 2014 ... tickets for the Guinness International Champions Cup Match between ... new Yankee Stadium in the Bronx has hosted countless big ... have the charm and history of the original Yankee Stadium, ... events in the New York City metro area. , ...
(Date:7/28/2014)... Scottsdale, Ariz (PRWEB) July 28, 2014 ... closed on a new camp property in Cornville, ... provides seriously ill children with the opportunity to ... the campers and families. The organization offers a ... ages 6-15 with chronic and life threatening illnesses ...
(Date:7/28/2014)... Quincy Bioscience, makers of the nation’s leading memory ... release of the fourth edition of The Brain Health ... , The Brain Health Guide is a unique resource ... to improve memory and promote optimal aging. Rather than ... Guide provides ways to help minimize common memory lapses ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... takes humans just milliseconds to look at someone,s face and ... study finds that certain facial features seem to trigger specific ... and size of the mouth, for example, appear directly linked ... to attractiveness. The study findings suggest that first ...
(Date:7/28/2014)... Ticket Down is reliable source ... Dallas, TX at the Cotton Bowl. The 2014 Guinness ... and it is an eight team tourney. The tournament ... teams from La Liga, Serie A, English Premier League, and ... out on the pitch include: Manchester United, Manchester City, ...
Breaking Medicine News(10 mins):Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3
... Products from AnaSpec, Accelrys, Almac Diagnostics, Seahorse Biosciences, BioFortis recognized ... ... San Francisco, CA (PRWEB) March 3, 2009 ... biotech companies that have won the Third Annual Best ...
... American Journal of Epidemiology , Oregon Research Institute ... a high-density of fast food outlets was associated with ... inches in waist circumference among neighborhood residents who frequently ... associated with a decrease of 2.7 pounds in weight ...
... types of child maltreatment are robust risk factors for ... that explored the influence of social environment on the ... appears in the current issue of Addictive Behaviors ... more alcoholic drinks on a single occasion at least ...
... 3 TouchMark, a division of Delphon Industries and industry ... is offering complimentary NRE (Non-Recurring Engineering or set-up fees) on ... customer who submits a new Pad Print order will not ... our customers, loyalty to TouchMark," says Jeanne Beacham, CEO. ...
... BOSTON, March 3 Important deadlines are approaching ... settlement related to the average wholesale prices of ... for the District of Massachusetts granted preliminary approval ... In the lawsuit, In re: Pharmaceutical Industry ...
... 3 Rochester Medical Corporation (Nasdaq: ROCM ... the company,s outstanding common shares pursuant to its previously ... repurchase shares from time to time on the open ... accordance with applicable SEC guidelines and regulations. Additionally, the ...
Cached Medicine News:Health News:Best New Product Awards Winners Named at Molecular Medicine Tri-Conference 2Health News:Best New Product Awards Winners Named at Molecular Medicine Tri-Conference 3Health News:Fast-food density and neighborhood walkability affect residents' weight and waist size 2Health News:How multiple childhood maltreatments lead to greater adolescent binge drinking 2Health News:How multiple childhood maltreatments lead to greater adolescent binge drinking 3Health News:Important Deadlines Near for $21 Million Class Action Settlement That Provides Consumers With Money Back for Over 200 Prescription Drugs 2Health News:Rochester Medical Renews Share Repurchase Activity 2
...
... FLEXILOG antimony pH catheters are designed for patient ... ,All catheters are number marked at 5cm intervals ... than sixteen individual models are available spanning most ... or multi-use models with one or two sensors., ...
... The Standard VersaFlex™ disposable pH ... nurses, and clinics worldwide for evaluating ... catheters for 24-hour esophageal pH monitoring. ... the smallest diameter esophageal catheter on ...
FLEXILOG accessory....
Medicine Products: